ALLUVI: A IN-DEPTH DIVE INTO RETATRUTIDE'S PROSPECTS

Alluvi, formerly BI 4744, presents a promising advance in obesity treatment. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates remarkable results in research studies, arguably outperforming existing GLP-1 site activators. Early findings s